SUMMARY Nine patients with severe myasthenia gravis, including ocular symptoms, who did not respond to anticholinesterase therapy were given prolonged courses of corticotrophin. In all patients except one there was an initial deterioration, sometimes necessitating assisted respiration, followed by a marked improvement which persisted for many weeks and occasionally months. It is concluded that corticotrophin should be continued for at least two weeks as the onset of the remission might be delayed. Repeated courses or small maintenance doses prolonged the remission. Fluid retention and hypokalaemia were common unwanted effects but necessitated stopping the treatment in only one patient.
Autoimmune phenomena have a role in myasthenia gravis (Simpson, 1960; White and Marshall, 1962; van der Geld, Feltkamp, and Oosterhuis, 1964) and there is an association between myasthenia gravis and diseases with autoimmune features (Piemme, 1964) . Corticotrophin therapy for myasthenia gravis was first used by Wolff (1949 and and Millikan and Eaton (1951) . In generalized myasthenia courses of corticotrophin for five to 10 days have been noted to produce a deterioration followed by improvement which may persist for several months (Freydberg, 1960; Grob and Namba, 1966; Osserman and Genkins, 1966;  Reis, Liljestrand, and Matell, 1966) . Recently, Cape and Utterback (1969) have suggested that maintenance injections weekly or twice monthly may prolong the remission. In the only report on the treatment of ocular myasthenia by Mount (1964a and b) , no significant improvement was detected after an eight day course of corticotrophin. The present study was performed to see whether an extended course of corticotrophin could produce an improvement in myasthenia in patients with ocular symptoms.
METHODS
All the patients with myasthenia attending a general neurological clinic were reviewed. Those with ocular myasthenia who were not obtaining full recovery with standard anticholinesterase treatment and in whom there was no contraindication to corticotrophin were admitted to the trial. None had previously received corticosteroids while suffering from myasthenia. During the initial few 11 days of their hospital admission their treatment was kept constant and they were assessed clinically. Edrophonium was used to confirm the diagnosis of myasthenia but produced little improvement when on full anticholinesterase treatment. In all patients, except case 8, the clinical state had remained unchanged for over three months. During the time they were given corticotrophin by intramuscular injection they were assessed clinically and biochemically. As the patients' previous conditions were stable the assessment could be made by comparison with their pretreatment state.
RESULTS
The important clinical findings are given in Table 1 and the results of treatment in reports (Freydberg, 1960; Grob and Namba, 1966 ; corticotrophin in 43 patients with ocular myasthenia, Osserman and Genkins, 1966; Reis et al., 1966) of 21 of whom received 40 u. corticotrophin gel for six short courses of corticotrophin therapy suggested days, then 30 u. for one day, and finished on the that the initial deterioration occurred during treat-eighth day with 20 u. He showed that this course of ment and the symptoms improved after injections corticotrophin produced no demonstrable improvewere stopped. This cannot be correct as, in the ment or deterioration in the signs and symptoms of present trial, treatment was continued throughout patients with ocular myasthenia two days and one the period of improvement. and three months after treatment. In view of the Corticotrophin undoubtedly improved the ocular many reports of an initial worsening before improvemyasthenia in the same way as the rest of the ment, the assessments were not made at the optimal musculature in all the patients except one, as would time and an eight day course would appear to be too have been expected from the previous reports on short. corticotrophin in generalized myasthenia (Freydberg, In the present study, the improvement started 1960; Grob and Namba, 1966; Osserman and about one week after treatment had been instituted Genkins, 1966; Reis et al., 1966) . Mount (1964a and and then continued, becoming maximal at about the b) reported a multicentred controlled trial of 14th day. In some the improvement continued for Cape and Utterback (1969) treated five patients with about 1,000 u. corticotrophin over 10 days. In three patients there was deterioration within the first week. Improvement followed in all patients within two weeks and was maintained for at least two months. Within six months they had all relapsed and three were given repeated courses with a similar incidence of initial deterioration. Maintenance therapy of 100 u. weekly or fortnightly was given to two patients after repeated intensive courses of corticotrophin and to one patient after a single intensive course. All three maintained their improvement during the period of 16 to 23 months during which they were followed. The dosage was not varied to see if smaller doses or wider intervals would have had a similar effect. Our patients were given corticotrophin for much longer than in most of the published reports and this probably explains why their improvement was maintained for such long periods. We would support the suggestion of Cape and Utterback (1969) Side-effects such as hypokalaemia and fluid retention occur and the long acting preparations may be given on alternate days.
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